Medication info
Pioglitazone Tablet (Pioglitazone Hydrochloride)

Pioglitazone Tablet (Pioglitazone Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Cosmax Pharma Co., Ltd.
Appearance
White round tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201901271 · Approved 2019.02.28 · Insurance code 055100860

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults · Children
Adult dosage
This drug is administered orally once daily, with or without food. Diabetes management should be individualized for each patient. Ideally, response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this drug should be administered for a sufficient period (at least 3 months) to evaluate changes in glycated hemoglobin, unless glycemic control in the patient with diabetes deteriorates. 1. Monotherapy This drug may be initiated as monotherapy at a dose of 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this drug does not provide a sufficient effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This drug may be administered in combination with a sulfonylurea, starting at an initial dose of 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin, starting at an initial dose of 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Precautions, Patients with renal impairment). Do not initiate treatment with this drug if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal) at the start of treatment (see Adverse Reactions and Precautions, Hepatic effects). Liver enzyme monitoring is recommended in all patients before starting therapy with this drug and periodically thereafter. There are no data on administration of this drug in combination with another thiazolidinedione.
Children's dosage
Use is not recommended in children under 18 years of age because there is no experience with its use.

Ingredients

Manufacturer
Cosmax Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control issues in patients with Type 2 diabetes
View approved original text

This drug is used to help control blood sugar levels in patients with Type 2 diabetes. It can be administered alone or in combination with sulfonylureas, metformin, or insulin when other oral hypoglycemic agents are insufficient. Additionally, nutritional counseling, weight loss, and exercise therapy should be conducted in conjunction with Type 2 diabetes patients. Such dietary and exercise therapies are very important for enhancing and maintaining the effects of drug therapy. This drug helps improve blood sugar control.

Dosage and Administration

Adult dosage

This drug is administered orally once daily, with or without food. Diabetes management should be individualized for each patient. Ideally, response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this drug should be administered for a sufficient period (at least 3 months) to evaluate changes in glycated hemoglobin, unless glycemic control in the patient with diabetes deteriorates. 1. Monotherapy This drug may be initiated as monotherapy at a dose of 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this drug does not provide a sufficient effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This drug may be administered in combination with a sulfonylurea, starting at an initial dose of 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin, starting at an initial dose of 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Precautions, Patients with renal impairment). Do not initiate treatment with this drug if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal) at the start of treatment (see Adverse Reactions and Precautions, Hepatic effects). Liver enzyme monitoring is recommended in all patients before starting therapy with this drug and periodically thereafter. There are no data on administration of this drug in combination with another thiazolidinedione.

Children's dosage

Use is not recommended in children under 18 years of age because there is no experience with its use.

Precautions

This drug is used for the treatment of Type 2 diabetes and helps improve insulin resistance and control blood sugar levels. During the use of this drug, caution should be taken regarding heart function. In some patients, this drug may induce or worsen heart failure, so if symptoms such as weight change, shortness of breath, or swelling occur, immediate consultation with a physician is necessary. Patients with heart failure or a history of heart failure should not take this drug. Additionally, this drug may cause fluid retention that can stress the heart, so it should be used with increased caution in patients with cardiovascular disease. During the use of this drug, if symptoms related to the bladder, such as hematuria, urinary disorders, or urgency, appear, the physician should be informed immediately to rule out bladder cancer. This drug should not be administered to patients with severe liver or kidney impairment, and regular liver function and kidney function tests should be performed. Women who are pregnant or may become pregnant should not take this drug, and premenopausal women should use appropriate contraceptive methods due to the risk of ovulation stimulation leading to pregnancy. This drug may increase the risk of hypoglycemia when combined with other hypoglycemic agents or insulin, so dose adjustments may be necessary when used in combination. Furthermore, this drug can cause weight gain and edema, so careful monitoring of weight changes and edema symptoms is advised. Elderly patients or those with decreased kidney and liver function should exercise additional caution when using this drug, and regular health checks are necessary. In case of overdose, even if special symptoms are absent, immediate consultation with healthcare professionals for appropriate action is advised. This drug has not been shown to be safe and effective in children; therefore, it should not be used in this population.

Side effects

Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, edema, upper respiratory tract infection, headache, sinusitis, myalgia, pharyngitis, abdominal bloating, weight gain, hypoglycemia, urinary tract infection, lumbago, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular factors, worsening of congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular anomalies, liver failure, diabetic macular edema accompanied by decreased vision, liver damage, fatigue, loss of appetite, discomfort in the right upper abdomen, dark urine, jaundice, anorexia, constipation, upper abdominal pain, chest pain, weakness, indigestion, nausea, dyspnea, itching, chest discomfort, tremors, chills, gastrointestinal disorder, abdominal pain, epigastric discomfort, numbness, muscle rigidity, head discomfort, increased liver enzymes, worsening of liver disease, hives, eczema, arthralgia, knee abnormality, arm weakness syndrome, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to light and should be stored in a tightly closed container protected from light. It should be kept in a cool place away from high humidity at temperatures between 15 and 30 degrees Celsius, preferably around 25 degrees.

Appearance and packaging

Appearance

White round tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.